David and Jane Chu Endowed Chair in Drug Discovery and Development, Professor of Pharmaceutical Sciences, Director of the Center for Protein Therapeutics, Executive Director of University Research Initiatives
Department of Pharmaceutical Sciences
Antibody-Drug Conjugates; Autoimmunity; Drug Targeting; Immunopharmacology; Mathematical Modeling; Monoclonal Antibodies; Pharmacodynamics; Pharmacokinetics; PK/PD; Preclinical Research
Research focuses on the utilization of pharmacokinetic and pharmacodynamic analyses and mathematical modeling to guide the discovery and development of new immunotherapies for cancer and autoimmunity.
Research Interests and Projects:
Research Interests and Current Projects:
1. Development of antibody conjugates for targeted, intra-cellular delivery of macromolecular toxins (CA204192)
2. Pharmacokinetic Strategies to Increase Monoclonal Antibody Uptake, Distribution, and Efficacy for Treatment of Solid Tumors (CA246785)
3. Inverse targeting strategies to decrease the off-site toxicity of antibody drug conjugate therapies for cancer (CA256928, CA261343)
4. Engineering monoclonal antibodies for improved pharmacokinetic properties
5. Investigation of sources of inter-individual variability in monoclonal antibody pharmacokinetics
6. Development of improved mathematical models for predicting the disposition and effects of monoclonal antibody drugs
7. Investigation of the role of FcRn in the absorption, distribution, and elimination of IgG antibodies
8. Development of antibody-based therapies to treat and prevent infection. Efforts are currently focused on prevention of infection by Treponema denticola (DE023080), S. aureus, and A. baumannii
9. Optimization of bispecific T-cell engagers, with primary focus on the application of PKPD modeling to guide discovery and development